Pfizer Denied New Trial In $200M Neurontin MDL

Law360, New York (July 29, 2011, 5:46 PM EDT) -- Pfizer Inc. on Wednesday lost its bid for a new trial in a multidistrict litigation in Massachusetts in which the drug company was ordered to pay $237 million to the Kaiser Foundation Health Plan for violating racketeering law in its marketing of pain drug Neurontin.

U.S. District Judge Patti B. Saris refused to reopen the evidence for Pfizer and its co-defendant, Pfizer unit Warner-Lambert Co., and shot down three of the defendants' arguments, including a claim that new evidence had surfaced.

The case is part of...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.